Acadia Healthcare Company, Inc. is an American provider of for-profit behavioral healthcare services. It operates a network of over 225 facilities across the United States and Puerto Rico.
Guggenheim's cut of Acadia Healthcare's price target signals growing concerns about regulatory pressures and debt levels, which can influence investor sentiment and the stock's valuation trajectory
Context & Background
Guggenheim lowered the target from $27 to $22
New York Medicaid and California staffing rules are expected to hit earnings
Acadia's debt of $2.45 billion exceeds its $1.55 billion market cap
Leadership change with CEO Debra Osteen returning
Other analysts have also downgraded the stock
What Happens Next
Acadia will report its fourth quarter 2025 earnings this week, during which CEO Osteen is expected to outline strategies to address headwinds; investors may adjust positions based on the new outlook and potential future analyst revisions
Frequently Asked Questions
Why did Guggenheim cut the price target?
Because of regulatory headwinds and a higher debt burden that could limit growth
What regulatory challenges are highlighted?
New York Medicaid's exclusion of out-of-state referrals and California's minimum staffing ratios
How does the debt level affect Acadia?
The debt of $2.45 billion compared to a $1.55 billion market cap indicates high leverage and potential risk
What should investors watch next?
The fourth quarter earnings report, CEO strategy, and any further analyst actions
}
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Gold prices rise on fresh Trump tariff jitters; Russia sold holding in January Five things to watch in markets in the week ahead Trump’s 15% global tariff; Waller to speak; oil drops - what’s moving markets U.S. stock futures drop on Trump tariff turmoil; Nvidia earnings in spotlight (South Africa Philippines Nigeria) Guggenheim cuts Acadia Healthcare stock price target on regulatory headwinds By Investing.com Analyst Ratings Published 02/23/2026, 07:20 AM Guggenheim cuts Acadia Healthcare stock price target on regulatory headwinds 0 ACHC -0.42% Investing.com - Guggenheim lowered its price target on Acadia Healthcare (NASDAQ:ACHC) to $22 from $27 while maintaining a Buy rating on the stock. The firm reduced its 2026 EBITDA estimate to $566 million to account for regulatory headwinds. New York Medicaid’s exclusion of out-of-state referrals and California minimum staffing ratios are expected to pressure results this year. Guggenheim raised its leverage estimate to approximately 4.4 times at year-end 2026 to reflect recent lawsuit developments. The firm previously flagged additional headwinds from PLGL late last year. This concern aligns with an InvestingPro analysis showing the company operates with a significant debt burden, with total debt standing at $2.45 billion against a market cap of just $1.55 billion. Returning CEO Debbie Osteen is expected to outline strategies to address operational challenges when the company reports fourth-quarter 2025 earnings this week. The analyst noted the company has faced difficulty navigating recent industry pressures. Acadia Healthcare currently trades at a multiple below 7 times, with an EV/EBITDA of 6.46 and shares at $16.79. The stock has fallen 57.65% over the past year, yet InvestingPro analysis suggests the company appears undervalued based on its Fair Value assessment. Guggenheim said achievable growth targets, improved bed-fill and capacity utilization, and potentia...
